The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Expires: July 31, 2015
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Inhibrx Biosciences, Inc. COM 45720N103 91,476,154 1,157,926 SH SOLE 1,157,926 0 0
MeiraGTx Holdings plc COM G59665102 96,972,009 12,197,737 SH SOLE 12,197,737 0 0
Novavax COM NEW 670002401 46,236,832 6,880,481 SH SOLE 6,880,481 0 0
AnaptysBio COM 032724106 39,846,536 821,917 SH SOLE 821,917 0 0
Immuneering Corp CLASS A COM 45254E107 17,822,318 2,708,559 SH SOLE 2,708,559 0 0
Eledon COM 28617K101 1,230,620 814,980 SH SOLE 814,980 0 0
Q32 Bio Inc. COM 746964105 810,356 244,083 SH SOLE 244,083 0 0
MapLight Therapeutics Inc. COM 56565P103 16,020,000 912,041 SH SOLE 912,041 0 0